# UnionLab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/unionlab

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.unionclin.com
- Total disclosed funding: $31M
- Latest round: Series B (Jan 28, 2026)
- Investors on record: 6

## About

Established in 2017 and based in Shanghai, China. Union-laboratory.com is a pharmaceutical company that focuses on research and development of molecular medicine and cancer drug. It also provides medical services, clinical operations, imaging assessment, data management and biometrics services. Their teams are distributed in more than 10 cities across the country. The company has 6 subsidiaries and more than 350 employees. The company's team has been responsible for dozens of clinical studies of new drugs, including antibodies, ADC drugs, small molecule targeted drugs, etc. One of remove its subsidiary Zhuoyan Zhineng developed multi-center collaborative intelligent clinical research system. In October 2018, the company launched clinical big data system. In February 2019, the company launched medical image reading system. By 2021, the company has raised 2 rounds of financing.

The company provides self-developed eDISC system which is an intelligent clinical research collaboration platform with integrating artificial intelligence, big data and cloud technology. In clinical aspects, the company cooperates with more than 10 principal investigators (PI) in the field of tumor involving liver cancer, breast cancer, pancreatic cancer, head and neck cancer, stomach, bowel cancer, lung cancer, blood cancer and many other cancers. Regarding to IRC team, it consists of 50 image reading experts from cancer specialist hospitals. The company cooperates with 260 researchers, 200 research centers distributed in 54 cities.

The company plans to deliver their eDISC system to more than 30 research centers for cooperation in 2022.

## Funding rounds

- Series B, Jan 28, 2026 — China International Capital Corporation
- Series A, Jun 3, 2021, $16M — Eastern Bell Capital, Cenova Ventures, Renjin Capital
- Series A, Nov 2, 2020, $15M — Cenova Ventures, Ruihe Xingye Asset, DHLT Investment

## Investors

- Cenova Ventures (https://capitalatlas.ai/funds/cenova-ventures) — Series A
- Ruihe Xingye Asset (https://capitalatlas.ai/funds/ruihe-xingye-asset) — Series A
- DHLT Investment (https://capitalatlas.ai/funds/dhlt-investment) — Series A
- Eastern Bell Capital — Series A
- Renjin Capital (https://capitalatlas.ai/funds/renjin-capital) — Series A
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B